Introduction
Multiple sclerosis (MS) is a progressive demyelinating neurological disease with an autoimmune component. 1 Although the incidence of MS is higher in women, its relapse rates are decreased during late pregnancy, 2, 3 and treatment with pregnancy levels of oestriol reduces central nervous system lesions. 4, 5 We demonstrated previously that relatively low doses of 17b-oestradiol (E 2 ) and oestriol confer potent protection against clinical and histological signs of experimental autoimmune encephalomyelitis (EAE), 6, 7 an animal model of MS. However, the molecular and cellular mechanisms by which oestrogens regulate MS and EAE have not been well characterized.
Several lines of evidence suggest that E 2 is a potent regulator of the immune system and may act directly on oligodendrocytes and neurons. We reported that E 2 treatment mitigated the production of proinflammatory cytokines, including tumour necrosis factor-a (TNF-a), release of chemokines and recruitment of inflammatory cells into the central nervous system, [6] [7] [8] [9] and boosted the frequency and function of regulatory T cells (Treg) through oestrogen receptor-a (ERa). 10 On the other hand, by evaluating the E 2 effect after transfer of encephalitogenic ERa +/+ or ERa )/) T cells into T-cell-deficient mice, we determined that E 2 treatment does not directly act on pathogenic T cells. 11 Similarly, anti-inflammatory cytokines including interleukin-10 (IL-10) and IL-4 were not required for E 2 regulation because E 2 was equally effective in wild-type mice and in IL-10 or IL-4 gene-deficient mice. 7 Thus, E 2 is a potent regulator of autoimmunity, but does not directly act on autoreactive T cells or through anti-inflammatory cytokines.
Programmed death 1 (PD-1) is a newly identified negative regulator of immune responses. 10 PD-1 gene-deficient (PD-1KO) mice develop autoimmune disorders similar to lupus-like glomerulonephritis, arthritis or dilated cardiomyopathy as early as 5 weeks of age. In MS patients, a PD-1 polymorphism was associated with disease progression, possibly as the result of a partial defect in PD-1-mediated inhibition of T-cell activation. 11 In the EAE model, it was shown that genetic disruption of PD-L1, an identified PD-1 ligand that can also bind to B7-1, converted an EAE-resistant mouse strain into a fully permissive one, 12 suggesting that the PD-1 pathway may be critically involved in the process of EAE induction. Our recent studies in PD-1KO mice showed that PD-1 plays an essential role in the initiation of EAE (C. Wang, Keywords: experimental autoimmune encephalomyelitis; interleukin-17; oestrogen; programmed death 1; regulatory T cells
, and that E 2 -induced Treg-cell suppression involves PD-1. 13 However, the precise role of PD-1 in E 2 -induced immunoregulation in EAE remains to be clarified.
Interleukin-17 is a critical proinflammatory cytokine and IL-17-producing helper T (Th17) cells may play a vital role in MS and EAE induction.
14,15 IL-17 can synergize with TNF-a, which is downregulated by E 2 7 and IL-1b to induce chemokine expression. 13, 16 Yet, it is not known whether or how E 2 can regulate the production of IL-17 in mice with EAE.
The results presented below demonstrate that E 2 treatment selectively upregulated the level of PD-1 in the CD4 + FoxP3 + Treg-cell compartment in immunized mice. The levels of PD-1 within the Treg-cell compartment, but not the frequency of Treg cells themselves, were closely linked to the disease suppressive activity of E 2 . Treatment with E 2 also profoundly reduced the production of IL-17. The E 2 -mediated protection against EAE and reduction of IL-17 production were completely abrogated in PD-1KO mice. Therefore, we conclude that PD-1 is a critical mediator of the immunoregulatory effects of E 2 .
Materials and methods

Mice
Mice used for these experiments were age-matched females (7-11 weeks old) that were rested for at least 7 days before treatment or immunization. The PD-1KO mice, which were backcrossed with C57BL/6 (B6) mice for 11 generations, were from Dr Honjo at Kyoto University (Kyoto, Japan). B6 mice and RAG1 )/) mice on the B10.PL background were purchased from the Jackson Laboratory (Bar Harbor, ME). MBP-TCRa/b doubletransgenic mice were a gift from Dr Juan LaFaille of New York University. Animals were housed and cared for according to institutional guidelines in the animal resource facility at the Veterans Affairs Medical Center, Portland, OR.
Reagents
Slow-releasing E 2 and placebo pellets were purchased from Innovative Research of America (Sarasota, FL). These pellets (3-mm diameter) are designed to release their contents at a constant rate over 60 days. Mouse (m) MOG-35-55 peptide was synthesized at Beckman Institute, Stanford University (Palo Alto, CA). Pertussis toxin (PTX) was purchased from List Biological Laboratories (Campbell, CA) and intracellular staining kits and all antibodies were purchased from eBioscience (San Diego, CA). Luminex Bio-Plex mouse cytokine assay kits were purchased from Bio-Rad (Hercules, CA).
Induction of EAE and treatment
Mice were inoculated subcutaneously in the flanks with 0Á2 ml of an emulsion containing 200 lg of mMOG-35-55 peptide and 200 lg of complete Freund's adjuvant containing 200 lg heat-killed Mycobacterium tuberculosis H37RA. On days 0 and 2, mice were injected intraperitonealy with 75 and 200 ng PTX, respectively. The mice were assessed daily for clinical signs of EAE: 0 = normal, 1 = limp tail or mild hind limb weakness, 2 = moderate hind limb weakness or mild ataxia, 3 = moderately severe hind limb weakness, 4 = severe hind limb weakness or mild forelimb weakness or moderate ataxia, 5 = paraplegia with no more than moderate forelimb weakness, and 6 = paraplegia with severe forelimb weakness or severe ataxia, moribund condition or dead. Pellets containing various doses of E 2 or placebo were implanted subcutaneously (dorsally) into mice 1 week before immunization. Serum levels of E 2 were monitored by radioimmunoassay as described previously.
6,17
Lymphocyte proliferation assay
Lymphocytes were harvested from spleens and lymph nodes and cultured in a 96-well flat-bottom tissue culture plate at 4 · 10 5 cells/well in stimulation medium in the presence of antigen-presenting cells (APC), irradiated (2500 rads) syngeneic thymocytes, at a ratio of 1 : 10 (T : APC), either with or without mMOG-35-55 peptide at varying concentrations. The cells were incubated for 3 days at 37°in 7% CO 2 , and pulsed with 0Á5 lCi 
Histopathology
Intact spinal columns were removed from experimental and control group mice. The spinal cords were dissected after fixation in 4% paraformaldehyde, dehydrated and embedded in paraffin before sectioning. To examine neuroinflammation, the sections were stained with haematoxylin and eosin (H & E). To examine demyelination the sections were stained with Luxol fast blue plus periodic acid Schiff. The sections were analysed by light microscopy after staining and were recorded with a digital camera.
Flow cytometry
For membrane staining (for CD4 and CD19), 1 million cells were stained at 4°in the dark with appropriate antibody dilutions in staining buffer (phosphate-buffered saline containing 0Á5% bovine serum albumin and 0Á02% sodium azide). Intracellular staining (for FoxP3 and PD-1) was performed following the protocol recommended by eBioscience. Briefly, 4 million cells were surface stained following standard procedures. After washing, the cells were fixed overnight and washed twice with 0Á5 ml permeabilization buffer. The cells were costained for 15 min with FcBlock and immunoglobulin G-peridinin chlorophyll protein followed 30 min later with fluorescently labelled antibodies to FoxP3 or isotype control. The cells were then washed twice with 2 ml permeabilization buffer and once with 1 ml staining buffer, and resuspended in staining buffer. Flow cytometry data were collected on LSRII and FACSCalibur flow cytometers (BD Bioscience, San Jose, CA), and analysed using FLOWJO software (Tree Star, Ashland, OR). Data represent 50 000-100 000 events.
Measurement of IL-17 production
Lymph node and spleen cells were cultured at 4 · 10 6 cells/well in a 24-well flat-bottom culture plate in stimulation medium (RPMI-1640, 1% sodium pyruvate, 1% L-glutamine, 0Á4% b 2 -mercaptoethanol, 10% fetal bovine serum) with 25 lg/ml mMOG-35-55 peptide for 48 hr. Supernatants were then harvested and stored at )80°until tested for cytokines. Culture supernatants were assessed for IL-17 production levels using a Luminex BioPlex mouse cytokine assay kit following the manufacturer's instructions.
Statistical analyses
Mean values from each experiment were compared statistically. Differences in daily clinical scores, peak scores and cumulative disease index (CDI) were evaluated by the Mann-Whitney test; incidence was evaluated by Fisher's exact test; disease onset, cytokine secretion, T-cell proliferation and flow cytometric data were compared by the unpaired Student's t-test. Data are represented as mean ± standard deviation of the mean (SD). All presented data represent one of two to four independent experiments. nized with mMOG-35-55 peptide. The mice were treated with 2Á5 mg/60 day release E 2 pellets 1 week before immunization and killed 27 days after immunization. The pellets were demonstrated to consistently release pregnancy levels of E 2 (1Á5-2 ng/ml) into the serum of treated mice. 18 As shown in Fig. 1(a (Fig. 1b) . Therefore, at pregnancy levels, E 2 treatment affected both the frequency and intensity of PD-1-expression in CD4 + FoxP3 + Treg cells.
Results
PD-1 level in Treg cells was correlated to EAE suppression
We subsequently investigated whether E 2 -induced upregulation of PD-1 in Treg cells was dose dependent. Indeed, E 2 pellets administered 7 days before immunization protected the mice from EAE induction in a dose-dependent manner (Fig. 2a) . Similarly, E 2 -induced upregulation of PD-1 within the Treg compartment was also dose-dependent. The level of PD-1 in Treg was linked closely to the reduction in disease severity induced by E 2 (Fig. 2b,c) . Interestingly, only the 2Á5 mg/60 day release E 2 pellets, which produce pregnancy levels of serum E 2 (not shown), but not pellets ranging from 0Á001 to 0Á71 mg, significantly increased the frequency of CD4 + FoxP3 + Treg cells. This result is in sharp contrast to the sensitive nature of E 2 -induced EAE suppression and upregulation of PD-1 expression in Treg, which increased after treatment with as little as 0Á025 mg/60 day release E 2 pellets. In unimmunized mice, however, E 2 failed to induce any change in PD-1 levels in Treg cells, even though the Treg-cell frequency was slightly, but not significantly, increased. Consequently, E 2 may only increase PD-1 expression in Treg cells upon induction of EAE.
PD-1 is indispensible for E 2 -induced protection against EAE
The contribution of PD-1 to E 2 -induced protection against EAE was evaluated in age-matched wild-type (WT; B6) and PD-1KO female mice. Mice were implanted with E 2 (2Á5 mg/60 day release) or placebo pellets 1 week before immunization. As shown in Fig. 3(a) , placebo-treated WT and PD-1KO mice developed severe EAE, whereas E 2 -treated WT mice developed no clinical signs of disease. In contrast, E 2 -treated PD-1KO mice had delayed onset but were not protected from EAE. T-cell responses to mMOG-35-55 peptide were more potent in PD-1KO mice compared with WT mice (Fig. 3b) , which was consistent with the negative regulatory nature of PD-1. There was little difference in lymphocyte proliferation responses between placebo-treated and E 2 -treated mice. Pathologically, all placebo-treated mice and E 2 -treated PD-1KO mice had substantial central nervous system infiltration and demyelination, whereas no pathological signs of EAE were observed in E 2 -treated WT mice (Fig. 3c) . Taken together, our results indicated a significant role for PD-1 in E 2 -stimulated protection against EAE. 
E 2 does not protect Treg-deficient mice against Spontaneous (Sp)-EAE
To study whether the PD-1 molecule expressed outside the Treg-cell compartment could mediate protection by E 2 , we tested the efficacy of E 2 in blocking Sp-EAE in Treg-deficient mice generated by crossing MBP-TCRa/b double-transgenic mice with Rag1 )/) mice on the B10.PL background. 19 As shown in Fig. 4(a) , no CD4 + FoxP3 + Treg cells were detectable in Treg-deficient mice, as expected. These mice typically develop Sp-EAE at about 10 weeks of age. As shown in Fig. 4(b) , neither E 2 nor placebo pellets administered when the Treg-deficient mice were ! 3 weeks old prevented them from developing Sp-EAE. The PD-1 molecules residing outside the Treg compartment did not, therefore, mediate the protective effects of E 2 .
E 2 treatment regulates IL-17 in a PD-1-dependent manner Lastly, we investigated the effect of E 2 treatment on the production of IL-17. As shown in Fig 
Discussion
The precise mechanisms by which oestrogens protect mice from EAE induction have not been completely defined. Our previous studies ruled out the possibility of direct E 2 regulation of encephalitogenic T cells by E 2 , 20 as well as the requirement for the anti-inflammatory cytokines, IL-4 and IL-10, 7 but suggested a link between PD-1 and Tregcell suppression in the E 2 regulatory mechanism. 13 We therefore evaluated critically the possible roles played by PD-1. We first demonstrated that E 2 -induced upregulation of PD-1 occurred selectively in the CD4 + FoxP3 + Treg-cell compartment. Indeed, the level of PD-1 expression in Treg cells correlated better with the disease-suppressing activity of E 2 than the percentage of PD-1 + Treg cells, which increased only when pregnancy levels of E 2 were given. 10 We then showed that the suppressive effects of E 2 on both EAE and IL-17 production were abrogated in PD-1KO mice. Finally, we demonstrated that E 2 could not inhibit Sp-EAE in Treg-deficient mice, so ruling out any participation of PD-1 expressed outside the Treg-cell compartment. Taken together, our results indicate that PD-1 expressed within the Treg-cell compartment serves as a critical mediator of E 2 -induced protection against EAE.
Treatment with E 2 is a powerful regulator of cytokines; E 2 decreases the production of proinflammatory cytokines, such as TNF-a, and increases the production of anti-inflammatory cytokines, such as IL-4 and IL-10. 7, 8 Although there is no doubt that these cytokines are important immunoregulators, their role in E 2 -induced protection against EAE is not clear. First, the anti-inflammatory cytokines, IL-4 and IL-10, are dispensable because E 2 could protect against EAE in IL-4 and IL-10 gene-deficient mice, even though their production was obviously enhanced in E 2 -treated WT mice. 7 On the other hand, E 2 treatment of WT mice decreased the production of the proinflammatory cytokine TNF-a. 7, 8 However, TNF-a gene-deficient mice on both the B6 and 129 backgrounds developed a more severe form of EAE characterized by increased inflammation and demyelination, which could be ameliorated by administration of TNF-a. 21 Under these circumstances, TNF-a appeared to have an antiinflammatory role in EAE, so it is difficult to argue that the decrease of TNF-a production by E 2 could account for the complete blockade of EAE induction by E 2 . The finding that E 2 drastically decreases the production of IL-17 in WT mice is significant because IL-17 and Th17 cells are known to be critically involved in the pathogenesis of MS and EAE. 15 It was reported previously that induction of EAE was prevented in IL-17 gene-deficient mice. 22 Our result in PD-1KO mice suggested that PD-1 expressed in Treg cells, which respond to low doses of E 2 , is a critical regulator of IL-17 production.
In summary, we demonstrated in this study that E 2 protected against EAE and downregulated IL-17 through a PD-1-dependent pathway that selectively involved Treg cells. Our results therefore shed new light on the mechanism through which oestrogens may regulate autoimmunity.
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